Exposure to Neuraminidase Inhibitors in Utero Not Harmful

Share this content:
Exposure to Neuraminidase Inhibitors in Utero Not Harmful
Exposure to Neuraminidase Inhibitors in Utero Not Harmful

WEDNESDAY, March 1, 2017 (HealthDay News) -- Exposure to neuraminidase inhibitors during pregnancy is not associated with adverse neonatal outcomes or congenital malformations, according to a study published online Feb. 28 in The BMJ.

Sophie Graner, M.D., Ph.D., from the Karolinska Institutet in Stockholm, and colleagues examined the possible effects of exposure to neuraminidase inhibitors during embryo-fetal life. Data were included for 5,824 exposed women and their infants and 692,232 non-exposed women.

The researchers found that in utero exposure to neuraminidase inhibitors was not associated with elevated risks of low birth weight (adjusted odds ratio [aOR], 0.77; 95 percent confidence interval [CI], 0.65 to 0.91), low Apgar score (aOR, 0.87; 95 percent CI, 0.67 to 1.14), preterm birth (adjusted hazard ratio, 0.97; 95 percent CI, 0.86 to 1.10), small-for-gestational-age birth (aOR, 0.72; 95 percent CI, 0.59 to 0.87), stillbirth (aOR, 0.81; 95 percent CI, 0.51 to 1.30), neonatal mortality (aOR, 1.13; 95 percent CI, 0.56 to 2.28), or neonatal morbidity (aOR, 0.92; 95 percent CI, 0.86 to 1.00). During the first trimester, there was no increased risk of congenital malformations overall in association with maternal exposure (aOR, 1.06; 95 percent CI, 0.77 to 1.48). In analysis restricted to oseltamivir alone, there were no significantly increased risks of any of the outcomes.

"The results support previously reported findings that the use of neuraminidase inhibitors is not associated with increased risks of adverse fetal or neonatal outcomes," the authors write.

One author disclosed financial ties to the Novo Nordisk Foundation.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

California Lawsuit Claims AbbVie Paid Doctors to Prescribe Humira

California Lawsuit Claims AbbVie Paid Doctors to Prescribe ...

Claims physicians prescribed Humira because of financial kickbacks, not as best drug for patient

Patient-Directed IV Remifentanil Cuts Epidural Conversions

Patient-Directed IV Remifentanil Cuts Epidural Conversions

Patient-controlled remifentanil reduces proportion of conversions versus intramuscular pethidine

Pediatricians Have Role in Supporting Transgender Youth

Pediatricians Have Role in Supporting Transgender Youth

Recommendations developed for comprehensive care for youth identifying as transgender, gender diverse

is free, fast, and customized just for you!




Already a member?

Sign In Now »